Skip to content

Pimavanserin: Innovation and Promise.

At ACADIA, we are developing pimavanserin as a potential first-in-class treatment for Parkinson's disease psychosis (PDP). The successful results from our pivotal Phase III study announced in November 2012 suggest that pimavanserin has the potential to transform the treatment landscape in PDP by providing an effective treatment of psychosis without compromising motor control and safety.

News

04/11/2013
ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA

03/20/2013
ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson's Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting

11/27/2012
ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinsons Disease Psychosis Trial

Webcasts

Webcast Image Webcast (Replay)
ACADIA Pharmaceuticals Conference Call to Discuss Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
04/11/13 at 8:00 a.m. ET
   
Webcast Image Webcast (Replay)
ACADIA Pharmaceuticals Conference Call to Present Top-line Results from its Pivotal Phase III Pimavanserin Parkinson's Disease Psychosis Trial
11/27/12 at 8:00 a.m. ET
   
Webcast Image Webcast (Replay)
ACADIA Pharmaceuticals - An Educational Program on Parkinson's Disease Psychosis
05/22/12 at 12:00 p.m. ET

back to top